“World malaria report 2019.” [Online]. Available: https://www.who.int/publications-detail/world-malaria-report-2019. [Accessed: 16-Dec-2019].
 K. L. Wilson, K. L. Flanagan, M. D. Prakash, and M. Plebanski, “Malaria vaccines in the eradication era: current status and future perspectives,” Expert Rev. Vaccines, vol. 18, no. 2, pp. 133–151, 2019, doi: 10.1080/14760584.2019.1561289.
 M. Zucca, S. Scutera, and D. Savoia, “New chemotherapeutic strategies against malaria, leishmaniasis and trypanosomiases,” Curr. Med. Chem., vol. 20, no. 4, pp. 502–526, 2013.
 D. A. Fidock, P. J. Rosenthal, S. L. Croft, R. Brun, and S. Nwaka, “Antimalarial drug discovery: efficacy models for compound screening,” Nat. Rev. Drug Discov., vol. 3, no. 6, pp. 509–520, Jun. 2004, doi: 10.1038/nrd1416.
 A. P. Mnzava, M. B. Macdonald, T. B. Knox, E. A. Temu, and C. J. Shiff, “Malaria vector control at a crossroads: public health entomology and the drive to elimination,” Trans. R. Soc. Trop. Med. Hyg., vol. 108, no. 9, pp. 550–554, Sep. 2014, doi: 10.1093/trstmh/tru101.
 M. Foley and L. Tilley, “Quinoline antimalarials: Mechanisms of action and resistance,” Int. J. Parasitol., vol. 27, no. 2, pp. 231–240, Feb. 1997, doi: 10.1016/S0020-7519(96)00152-X.
 J. Achan et al., “Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria,” Malar. J., vol. 10, p. 144, May 2011, doi: 10.1186/1475-2875-10-144.
 B. E. Monjol and M. F. Useh, “Detection of Plasmodium falciparum chloroquine resistance transporter (PfCRT) mutant gene amongst malaria-infected pregnant women in Calabar, Nigeria,” Ann. Parasitol., vol. 63, no. 4, pp. 323–330, 2017.
 D. Payne, “Spread of chloroquine resistance in Plasmodium falciparum,” Parasitol. Today, vol. 3, no. 8, pp. 241–246, Aug. 1987, doi: 10.1016/0169-4758(87)90147-5.
 H. A. Antony and S. C. Parija, “Antimalarial drug resistance: An overview,” Trop. Parasitol., vol. 6, no. 1, pp. 30–41, 2016, doi: 10.4103/2229-5070.175081.
 A. Sowunmi et al., “Therapeutic efficacy and effects of artemisinin-based combination treatments on uncomplicated Plasmodium falciparum malaria -associated anaemia in Nigerian children during seven years of adoption as first-line treatments,” Infect. Dis. Poverty, vol. 6, Feb. 2017, doi: 10.1186/s40249-016-0217-7.
 “WHO | Antimalarial drug resistance in the Greater Mekong Subregion: How concerned should we be?,” WHO. [Online]. Available: http://www.who.int/malaria/media/drug-resistance-greater-mekong-qa/en/. [Accessed: 06-Mar-2018].
 R. Amato et al., “Origins of the current outbreak of multidrug-resistant malaria in southeast Asia: a retrospective genetic study,” Lancet Infect. Dis., vol. 18, no. 3, pp. 337–345, Mar. 2018, doi: 10.1016/S1473-3099(18)30068-9.
 D. Zofou et al., “Control of malaria and other vector-borne protozoan diseases in the tropics: enduring challenges despite considerable progress and achievements,” Infect. Dis. Poverty, vol. 3, p. 1, Jan. 2014, doi: 10.1186/2049-9957-3-1.
 M. Imwong et al., “The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study,” Lancet Infect. Dis., vol. 17, no. 5, pp. 491–497, May 2017, doi: 10.1016/S1473-3099(17)30048-8.
 F.-S. Li and J.-K. Weng, “Demystifying traditional herbal medicine with modern approach,” Nat. Plants, vol. 3, p. 17109, Jul. 2017, doi: 10.1038/nplants.2017.109.
 S. Norn, H. Permin, P. R. Kruse, and E. Kruse, “[From willow bark to acetylsalicylic acid],” Dan. Med. Arbog, vol. 37, pp. 79–98, 2009.
 T. F. Whayne, “Clinical Use of Digitalis: A State of the Art Review,” Am. J. Cardiovasc. Drugs Drugs Devices Interv., vol. 18, no. 6, pp. 427–440, Dec. 2018, doi: 10.1007/s40256-018-0292-1.
 S. Norn, P. R. Kruse, and E. Kruse, “[History of opium poppy and morphine],” Dan. Med. Arbog, vol. 33, pp. 171–184, 2005.
 A. Vickers, C. Zollman, and R. Lee, “Herbal medicine,” West. J. Med., vol. 175, no. 2, pp. 125–128, Aug. 2001.
 H. Permin, S. Norn, E. Kruse, and P. R. Kruse, “On the history of Cinchona bark in the treatment of Malaria,” Dan. Med. Arbog, vol. 44, pp. 9–30, 2016.
 G. D. Shanks, “Historical Review: Problematic Malaria Prophylaxis with Quinine,” Am. J. Trop. Med. Hyg., vol. 95, no. 2, pp. 269–272, Aug. 2016, doi: 10.4269/ajtmh.16-0138.
 G. Gachelin, P. Garner, E. Ferroni, U. Tröhler, and I. Chalmers, “Evaluating Cinchona bark and quinine for treating and preventing malaria,” J. R. Soc. Med., vol. 110, no. 1, pp. 31–40, Jan. 2017, doi: 10.1177/0141076816681421.
 S. de Ridder, F. van der Kooy, and R. Verpoorte, “Artemisia annua as a self-reliant treatment for malaria in developing countries,” J. Ethnopharmacol., vol. 120, no. 3, pp. 302–314, Dec. 2008, doi: 10.1016/j.jep.2008.09.017.
 “Traditional Medicine,” WHO | Regional Office for Africa. [Online]. Available: https://www.afro.who.int/health-topics/traditional-medicine. [Accessed: 01-Apr-2019].
 S.-Y. Pan et al., “Historical Perspective of Traditional Indigenous Medical Practices: The Current Renaissance and Conservation of Herbal Resources,” Evid.-Based Complement. Altern. Med. ECAM, vol. 2014, 2014, doi: 10.1155/2014/525340.
 K. M. Hoffmann et al., “Kampo Medicine: Evaluation of the Pharmacological Activity of 121 Herbal Drugs on GABAA and 5-HT3A Receptors,” Front. Pharmacol., vol. 7, Jul. 2016, doi: 10.3389/fphar.2016.00219.
 X. Chen et al., “Identification of crude drugs in the Japanese pharmacopoeia using a DNA barcoding system,” Sci. Rep., vol. 7, p. 42325, Feb. 2017, doi: 10.1038/srep42325.
 M. Arai, S. Katai, S. Muramatsu, T. Namiki, T. Hanawa, and S. Izumi, “Current status of Kampo medicine curricula in all Japanese medical schools,” BMC Complement. Altern. Med., vol. 12, p. 207, Nov. 2012, doi: 10.1186/1472-6882-12-207.
 S. Yakubo et al., “Pattern Classification in Kampo Medicine,” Evid.-Based Complement. Altern. Med. ECAM, vol. 2014, 2014, doi: 10.1155/2014/535146.
 T. Yoshino et al., “Predicting Japanese Kampo formulas by analyzing database of medical records: a preliminary observational study,” BMC Med. Inform. Decis. Mak., vol. 16, no. 1, Sep. 2016, doi: 10.1186/s12911-016-0361-9.
 Y. Motoo, T. Seki, and K. Tsutani, “Traditional Japanese medicine, Kampo: its history and current status,” Chin. J. Integr. Med., vol. 17, no. 2, pp. 85–87, Feb. 2011, doi: 10.1007/s11655-011-0653-y.
 “TradMPD Information on experimental crude drug extracts.” [Online]. Available: http://dentomed.u-toyama.ac.jp/en/information_on_experimental_crude_drug_extracts/. [Accessed: 28-Jul-2017].
 A. Fujii, T. Okuyama, K. Wakame, T. Okumura, Y. Ikeya, and M. Nishizawa, “Identification of anti-inflammatory constituents in Phellodendri Cortex and Coptidis Rhizoma by monitoring the suppression of nitric oxide production,” J. Nat. Med., vol. 71, no. 4, pp. 745–756, Oct. 2017, doi: 10.1007/s11418-017-1107-4.
 N. Oshima, T. Shimizu, Y. Narukawa, N. Hada, and F. Kiuchi, “Quantitative analysis of the anti-inflammatory activity of orengedokuto II: berberine is responsible for the inhibition of NO production,” J. Nat. Med., vol. 72, no. 3, pp. 706–714, Jun. 2018, doi: 10.1007/s11418-018-1209-7.
 Y. Chen, Y. Xian, Z. Lai, S. Loo, W. Y. Chan, and Z.-X. Lin, “Anti-inflammatory and anti-allergic effects and underlying mechanisms of Huang-Lian-Jie-Du extract: Implication for atopic dermatitis treatment,” J. Ethnopharmacol., vol. 185, pp. 41–52, Jun. 2016, doi: 10.1016/j.jep.2016.03.028.
 N. Wang, H.-Y. Tan, L. Li, M.-F. Yuen, and Y. Feng, “Berberine and Coptidis Rhizoma as potential anticancer agents: Recent updates and future perspectives,” J. Ethnopharmacol., vol. 176, pp. 35–48, Dec. 2015, doi: 10.1016/j.jep.2015.10.028.
 Z. Xu et al., “Rhizoma Coptidis and Berberine as a Natural Drug to Combat Aging and Aging-Related Diseases via Anti-Oxidation and AMPK Activation,” Aging Dis., vol. 8, no. 6, pp. 760–777, Dec. 2017, doi: 10.14336/AD.2016.0620.
 M. Nonaka, Y. Murata, R. Takano, Y. Han, Md. H. Bin Kabir, and K. Kato, “Screening of a library of traditional Chinese medicines to identify anti-malarial compounds and extracts,” Malar. J., vol. 17, p. 244, Jun. 2018, doi: 10.1186/s12936-018-2392-4.
 K. Watanabe et al., “Traditional Japanese Kampo Medicine: Clinical Research between Modernity and Traditional Medicine—The State of Research and Methodological Suggestions for the Future,” Evid.-Based Complement. Altern. Med. ECAM, vol. 2011, 2011, doi: 10.1093/ecam/neq067.
 W. Trager and J. B. Jenson, “Cultivation of malarial parasites,” Nature, vol. 273, no. 5664, pp. 621–622, Jun. 1978, doi: 10.1038/273621a0.
 E. Borenfreund and H. Babich, “In vitro cytotoxicity of heavy metals, acrylamide, and organotin salts to neural cells and fibroblasts,” Cell Biol. Toxicol., vol. 3, no. 1, pp. 63–73, Mar. 1987, doi: 10.1007/BF00117826.
 F. Mosaddeque et al., “Prediction Model for Antimalarial Activities of Hemozoin Inhibitors by Using Physicochemical Properties,” Antimicrob. Agents Chemother., vol. 62, no. 5, pp. e02424-17, May 2018, doi: 10.1128/AAC.02424-17.
 M. N. Shuaibu, M. Kikuchi, M. S. Cherif, G. K. Helegbe, T. Yanagi, and K. Hirayama, “Selection and identification of malaria vaccine target molecule using bioinformatics and DNA vaccination,” Vaccine, vol. 28, no. 42, pp. 6868–6875, Oct. 2010, doi: 10.1016/j.vaccine.2010.08.019.
 A. R. Parhizgar and A. Tahghighi, “Introducing New Antimalarial Analogues of Chloroquine and Amodiaquine: A Narrative Review,” Iran. J. Med. Sci., vol. 42, no. 2, pp. 115–128, Mar. 2017.
 M. Cañón, H. Diaz, and A. Olarte, “Mathematical model for the spread of drug resistance in Plasmodium falciparum parasite considering transmission conditions,” J. Theor. Biol., vol. 435, pp. 1–11, Dec. 2017, doi: 10.1016/j.jtbi.2017.09.001.
 C. Nsanzabana, D. Djalle, P. J. Guérin, D. Ménard, and I. J. González, “Tools for surveillance of anti-malarial drug resistance: an assessment of the current landscape,” Malar. J., vol. 17, Feb. 2018, doi: 10.1186/s12936-018-2185-9.
 M. Fadaeinasab, H. Taha, P. N. M. Fauzi, H. M. Ali, and A. Widyawaruyanti, “Anti-malarial Activity of Isoquinoline Alkaloids from the Stem Bark of Actinodaphne macrophylla,” Nat. Prod. Commun., vol. 10, no. 9, pp. 1541–1542, Sep. 2015.
 B.-L. Ma et al., “Increased Systemic Exposure to Rhizoma Coptidis Alkaloids in Lipopolysaccharide-Pretreated Rats Attributable to Enhanced Intestinal Absorption,” Drug Metab. Dispos., vol. 40, no. 2, pp. 381–388, Feb. 2012, doi: 10.1124/dmd.111.041152.
 K. Zou et al., “Advances in the study of berberine and its derivatives: a focus on anti-inflammatory and anti-tumor effects in the digestive system,” Acta Pharmacol. Sin., vol. 38, no. 2, pp. 157–167, Feb. 2017, doi: 10.1038/aps.2016.125.
 N. Silikas, D. L. C. Mccall, D. Sharples, W. M. Watkins, R. D. Waigh, and J. Barber, “The Antimalarial Activity of Berberine and Some Synthetic Analogues,” Pharm. Pharmacol. Commun., vol. 2, no. 1, pp. 55–58, Jan. 1996, doi: 10.1111/j.2042-7158.1996.tb00532.x.
 H. Mahmoudvand et al., “Antifungal, Antileishmanial, and Cytotoxicity Activities of Various Extracts of Berberis vulgaris (Berberidaceae) and Its Active Principle Berberine,” ISRN Pharmacol., vol. 2014, Mar. 2014, doi: 10.1155/2014/602436.
 H.-C. Chou et al., “Proteomic and redox-proteomic analysis of berberine-induced cytotoxicity in breast cancer cells,” J. Proteomics, vol. 75, no. 11, pp. 3158–3176, Jun. 2012, doi: 10.1016/j.jprot.2012.03.010.
 L. El khalki, M. Tilaoui, A. Jaafari, H. Ait Mouse, and A. Zyad, “Studies on the Dual Cytotoxicity and Antioxidant Properties of Berberis vulgaris Extracts and Its Main Constituent Berberine,” Adv. Pharmacol. Sci., vol. 2018, Jan. 2018, doi: 10.1155/2018/3018498.
 J. Su et al., “Pharmacokinetics and Brain Distribution and Metabolite Identification of Coptisine, a Protoberberine Alkaloid with Therapeutic Potential for CNS Disorders, in Rats,” Biol. Pharm. Bull., vol. 38, no. 10, pp. 1518–1528, 2015, doi: 10.1248/bpb.b15-00293.
 Y. Yan et al., “Pharmacokinetics and tissue distribution of coptisine in rats after oral administration by liquid chromatography–mass spectrometry,” Biomed. Chromatogr., p. n/a-n/a, Jan. 2017, doi: 10.1002/bmc.3918.
 S. Pushpakom et al., “Drug repurposing: progress, challenges and recommendations,” Nat. Rev. Drug Discov., Oct. 2018, doi: 10.1038/nrd.2018.168.
 S. M. Corsello et al., “The Drug Repurposing Hub: a next-generation drug library and information resource,” Nat. Med., vol. 23, no. 4, pp. 405–408, Apr. 2017, doi: 10.1038/nm.4306.
 N. R. Rabinovich, “Ivermectin: repurposing an old drug to complement malaria vector control,” Lancet Infect. Dis., vol. 18, no. 6, pp. 584–585, Jun. 2018, doi: 10.1016/S1473-3099(18)30176-2.